These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 24969552

  • 1. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.
    Moon du G, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, Yoon CY, Byun SS, Park HS, Cheon J.
    Int J Oncol; 2014 Sep; 45(3):1027-35. PubMed ID: 24969552
    [Abstract] [Full Text] [Related]

  • 2. Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells.
    Kim HJ, Gong MK, Yoon CY, Kang J, Yun M, Cho NH, Rha SY, Choi YD.
    Yonsei Med J; 2020 Jul; 61(7):587-596. PubMed ID: 32608202
    [Abstract] [Full Text] [Related]

  • 3. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS, Hong SK, Oh MM, Yoon CY, Jeong SJ, Byun SS, Cheon J, Lee SE, Moon du G.
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [Abstract] [Full Text] [Related]

  • 4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K, Hamacher A, Engelke LH, Kassack MU.
    BMC Cancer; 2017 Nov 03; 17(1):711. PubMed ID: 29100507
    [Abstract] [Full Text] [Related]

  • 6. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
    Matsushima M, Kikuchi E, Matsumoto K, Hattori S, Takeda T, Kosaka T, Miyajima A, Oya M.
    Int J Oncol; 2015 Jul 03; 47(1):377-83. PubMed ID: 25963317
    [Abstract] [Full Text] [Related]

  • 7. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 03; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
    Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF.
    PLoS One; 2013 Jul 03; 8(3):e59879. PubMed ID: 23533654
    [Abstract] [Full Text] [Related]

  • 10. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.
    Cancer Res; 2008 Oct 01; 68(19):8022-30. PubMed ID: 18829560
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S, Flentje M, Djuzenova CS.
    Radiat Oncol; 2015 Oct 24; 10():214. PubMed ID: 26498922
    [Abstract] [Full Text] [Related]

  • 14. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.
    Mol Cancer; 2013 May 24; 12():46. PubMed ID: 23705826
    [Abstract] [Full Text] [Related]

  • 15. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.
    PLoS One; 2012 May 24; 7(5):e37431. PubMed ID: 22662154
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A, Li H, Li R, Lu L, Wu X.
    Oncol Rep; 2018 Oct 24; 40(4):2353-2362. PubMed ID: 30066933
    [Abstract] [Full Text] [Related]

  • 18. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

  • 19. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S, Soltani A, Shirzad H, Esmaeil N, Ghatrehsamani M.
    Biomed Pharmacother; 2017 Aug 01; 92():39-45. PubMed ID: 28528184
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Aug 01; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.